Question · asked by 1 review
Riluzole vs placebo: Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production Cooper 2008 reported 3 speech measures: ICARS speech subscale. Scale from: 0 to 8. Higher scores indicate greater clinical severity Syl...
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Riluzole vs placebo Short‐term (within 1 month) change in isolated movement, objective and subjective measures of speech production ICARS. Scale from: 0 to 8. Higher scores indicate more severe speech disorder. · people with speech disorder resulting from hereditary ataxias Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes (2014) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 38 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes 2014 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.